Northwire Canada EditionWednesday, July 15, 2026
Sign inSubscribe
Northwire
⌕
SGQ 0.400 +5.3% GMX 1.87 −1.6% ALM 0.310 +0.0% WCU 0.010 +0.0% NTH 0.155 −6.1% GGM 0.035 +0.0% FG 0.035 +0.0% EFR 17.73 −4.7% IVN 10.48 −2.8% MASS 0.090 +0.0% LIF 26.54 −2.4% CPAU 0.155 +0.0% PTX 0.105 −4.5% VENT 0.160 +0.0% ANK 0.278 −4.3% ODV 3.36 −0.3% SGQ 0.400 +5.3% GMX 1.87 −1.6% ALM 0.310 +0.0% WCU 0.010 +0.0% NTH 0.155 −6.1% GGM 0.035 +0.0% FG 0.035 +0.0% EFR 17.73 −4.7% IVN 10.48 −2.8% MASS 0.090 +0.0% LIF 26.54 −2.4% CPAU 0.155 +0.0% PTX 0.105 −4.5% VENT 0.160 +0.0% ANK 0.278 −4.3% ODV 3.36 −0.3%
Financings

Cannabix Technologies announces Non-Brokered LIFE Private Placement

By The Northwire Desk — AI Analysis Feb 06, 2026 · 19:00 BLO · 0.58 Cannabix Technologies Inc.
BLO · Price

Executive Summary

  • Cannabix Technologies Inc. announces a non‑brokered private placement of 1 M–2 M units at CDN$0.50 per unit, targeting gross proceeds of CDN$500K–$1 M.
  • Each unit includes one common share and one non‑transferable warrant exercisable at CDN$0.65 per share for up to 24 months, with an acceleration clause if the share price reaches CDN$0.75 for ten consecutive trading days.
  • Net proceeds will be used for manufacturing inventory, labour, general & administrative expenses (including investor relations) and other working capital needs.

Key Details

  • Units Offered: Minimum 1,000,000 – Maximum 2,000,000 units at CDN$0.50 each.
  • Gross Proceeds Target: Minimum CDN$500,000 – Maximum CDN$1,000,000.
  • Unit Composition:
  • 1 common share (“Share”).
  • 1 non‑transferable common share purchase warrant (“Warrant”).
  • Warrant Terms:
  • Exercise price: CDN$0.65 per Share.
  • Exercisable for 24 months from issuance.
  • Acceleration right triggered if the CSE share price ≥ CDN$0.75 for 10 consecutive trading days; warrants would then expire 30 calendar days after Company notice.
  • Insider Participation: Insiders may subscribe on the same terms; participation qualifies as a related‑party transaction but is exempt from formal valuation and minority‑shareholder approval under MI 61‑101 because it does not exceed 25% of market cap. No insider proceeds will be used to repay debt or fund insider‑related transactions.
  • Use of Net Proceeds: Funding manufacturing inventory, labour costs, general & administrative expenses (including investor relations), and unallocated working capital.
  • Waiver Received: An existing contractual participation right holder has waived the right to participate in this offering.
  • Offering Availability: Open to Canadian residents (excluding Quebec) and U.S. persons under the Listed Issuer Financing Exemption; not offered in the United States or other jurisdictions where it would be unlawful.

Notable Quotes

“Rav Mlait”, CEO, Cannabix Technologies Inc. – on behalf of the Board of Directors.

Read the original news release →

More from Cannabix Technologies Inc.

Jun 29, 2026 · 08:45

Cannabix scales its breath-based THC and alcohol screening hardware into global mining and industrial sectors, but revenue remains negligible against operating burn.

Production / Operations Jun 15, 2026 · 08:45

Cannabix Technologies Inc.

M&A / Property May 29, 2026 · 08:45

Cannabix Expands Australian Footprint as MBT Certification Progresses Amidst Volatility

Production / Operations May 13, 2026 · 08:45

Cannabix Secures UL/CSA Certs, Clears Path for Gov Tenders Amidst Steady Commercial Rollout

Regulatory May 04, 2026 · 08:45

Cannabix Executes Commercial Rollout Amidst Dilution Concerns

Production / Operations Apr 20, 2026 · 08:45

Cannabix Breath Test Gains Traction in US Manufacturing Sector Following Commercial Launch

M&A / Property